Araştırma Makalesi
BibTex RIS Kaynak Göster

Examining the relationship between the atherogenic index of plasma and coronary plaque burden: insights from a retrospective intravascular ultrasound analysis

Yıl 2024, Cilt: 5 Sayı: 1, 23 - 28, 29.02.2024
https://doi.org/10.47582/jompac.1421199

Öz

Aims: In the context of coronary artery disease development, inflammation and lipid metabolism play significant roles. This study explores the link between the Atherogenic Index of Plasma (AIP) and plaque burden in intravascular ultrasound (IVUS) examined patients.
Methods: A retrospective analysis included seventy-six consecutive IVUS patients from June 2020 to May 2023. AIP, calculated as the log of plasma triglyceride divided by high-density lipoprotein cholesterol, measured atherogenicity. Plaque burden, a percentage, was determined by dividing the total plaque area by the total vessel area. Multivariate regression and Spearman’s correlation analyzed the relationship between AIP and high plaque burden.
Results: The median age was 59 years, with 72.4% males. Univariate analysis identified age, diabetes mellitus (DM), smoking, and AIP as plaque burden predictors. Multivariate analysis showed AIP (OR=1.53, 95% CI:1.12-2.02, p=0.021) and DM independently predicted high plaque burden (OR=1.03, 95% CI:1.01-1.45, p=0.044). Spearman’s correlation indicated a positive correlation between AIP and high plaque burden (rho: 0.682, p<0.05).
Conclusion: This study suggests AIP, a surrogate marker of atherosclerosis, may predict plaque burden in IVUS-examined patients.

Kaynakça

  • Ford T J, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart. 2018;104:284-292.
  • Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 20017;17(11):1410-1422.
  • Knuuti J, Wijns W, Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Europ Heart J. 2019;41(3):407‑477.
  • Raygor V, Khera A. New recommendations and revised concepts in recent guidelines on the management of dyslipidemias to prevent cardiovascular disease: The 2018 ACC/AHA and 2019 ESC/EAS guidelines. Curr Cardiol Reports. 2019;22(9):87.
  • Erdoğan A, İnan D, Genç Ö, et al. The triglyceride–glucose index might be a better indicator for predicting poor cardiovascular outcomes in chronic coronary syndrome. J Clin Med. 2023;12(19): 6201.
  • Zhu XW, Deng FY, Lei SF. Meta-analysis of the atherogenic index of plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Prim Care Diabetes. 2015;9(1):60-67.
  • Cai G, Shi G, Xue S, Lu W. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96(37):e8058.
  • Yueqiao S, Wenjun F, Chao H, Jingyi L, Lixian S. Atherogenic index of plasma, triglyceride- glucose index and monocyte-to-lymphocyte ratio for predicting subclinical coronary artery disease. Am J Med Sci. 2021;362(3):285-290.
  • Won KB, Heo R, Park HB, et al. Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors. Atherosclerosis. 2021;324:46-51.
  • Mao Q, Zhou D, Li Y, Wang Y, Xu SC, Zhao XH. The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-ST-segment elevation acute coronary syndrome. Dis Markers. 2019;2019:6891537.
  • Nam JS, Kim MK, Nam JY, et al. Association between the atherogenic index of plasma and coronary artery calcification progression in Korean adults. Lipids Health Dis. 2020;19(1):1-7.
  • Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 20017;17(11):1410-1422.
  • Cheng JM, Suoniemi M, Kardys I, et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015;243(2):560-566.
  • Yan PF, Liu L, Yuan J, Xu CX, Song D, Yan H. The racial differences in the clinical outcomes of intravascular ultrasound-guided percutaneous coronary intervention: a systematic review and meta-analysis. Am J Cardiol. 2023;203:193-202.
  • 15. Saito Y, Kobayashi Y, Fujii K, et al. CVIT 2023 clinical expert consensus document on intravascular ultrasound. Cardiovasc Inter Ther. 2023;39(1):1-14.
  • Räber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018;39(35):3281-3300.
  • Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51(6):1908-1919.
  • Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-1252.
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
  • He Y , Li Z, Yu L, et al. Association between the atherogenic index of plasma and carotid artery plaques in patients with coronary heart disease in different glucose metabolism states: an RCSCD-TCM study in Tianjin, China. Endocrine. 2023;81(2):252-261.
  • Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34(7):583-588.
  • Dobiásová M, Frohlich J, Sedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52:566-571.
  • Shen S, Lu Y, Qi H, et al. Association between ideal cardiovascular health and the atherogenic index of plasma. Medicine. 2016;95(24):e3866.
  • Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran. 2015;29:240.
  • Ono M, Kawashima H, Hara H, et al. Advances in IVUS/OCT and future clinical perspective of a novel hybrid catheter system in coronary imaging. Front Cardiovasc Med. 2020;31:7-119.

Plazma aterojenik indeks ile koroner plak yükü arasındaki ilişkinin incelenmesi: retrospektif bir intravasküler ultrason grüntülerinden analizler

Yıl 2024, Cilt: 5 Sayı: 1, 23 - 28, 29.02.2024
https://doi.org/10.47582/jompac.1421199

Öz

Amaç: Koroner arter hastalığı gelişiminde, inflamasyon ve lipid metabolizması önemli rol oynamaktadır. Bu çalışma, plazma aterojenik indeks (AIP) ve intravasküler ultrason (IVUS) ile incelenen hastalardaki plak yükü arasındaki bağlantıyı araştırmaktadır.

Materyal ve Metod: Bu retrospektif çalışma, Haziran 2020'den Mayıs 2023'e kadar olan dönemde yapılan yetmiş altı ardışık IVUS hastasını içermektedir. AIP, plazma trigliseridin yüksek yoğunluklu lipoprotein kolesterole bölünmesi ile hesaplanan aterojenik bir skordur. Plak yükü, yüzde olarak, toplam plak alanının toplam damar alanına bölünmesiyle belirlendi. Çoklu regresyon ve Spearman'ın korelasyon analizi , AIP ile yüksek plak yükü arasındaki ilişkiyi analiz etmek için kullanıldı.

Sonuçlar: Hastalrın ortanca yaşı 59 yıl, %72.4'ü erkekti. Univariate analizde yaş, diabetes mellitus, sigara içme ve AIP plak yükü tahmincileri olarak belirlendi. Çoklu analiz AIP'nin (OR=1.53, %95 CI: 1.12-2.02, p=0.021) ve DM'nin bağımsız olarak yüksek plak yükünü tahmin ettiğini gösterdi (OR=1.03, %95 CI: 1.01-1.45, p=0.044). Spearman'ın korelasyon analizi , AIP ve yüksek plak yükü arasında pozitif bir ilişki olduğunu gösterdi (rho: 0.682, p < 0.05).

Sonuç: Bu çalışma, aterosklerozun bir belirteci olan AIP'nin, IVUS ile incelenen hastalarda plak yükünü tahmin edebileceğini göstermektedir.

Kaynakça

  • Ford T J, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart. 2018;104:284-292.
  • Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 20017;17(11):1410-1422.
  • Knuuti J, Wijns W, Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Europ Heart J. 2019;41(3):407‑477.
  • Raygor V, Khera A. New recommendations and revised concepts in recent guidelines on the management of dyslipidemias to prevent cardiovascular disease: The 2018 ACC/AHA and 2019 ESC/EAS guidelines. Curr Cardiol Reports. 2019;22(9):87.
  • Erdoğan A, İnan D, Genç Ö, et al. The triglyceride–glucose index might be a better indicator for predicting poor cardiovascular outcomes in chronic coronary syndrome. J Clin Med. 2023;12(19): 6201.
  • Zhu XW, Deng FY, Lei SF. Meta-analysis of the atherogenic index of plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Prim Care Diabetes. 2015;9(1):60-67.
  • Cai G, Shi G, Xue S, Lu W. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96(37):e8058.
  • Yueqiao S, Wenjun F, Chao H, Jingyi L, Lixian S. Atherogenic index of plasma, triglyceride- glucose index and monocyte-to-lymphocyte ratio for predicting subclinical coronary artery disease. Am J Med Sci. 2021;362(3):285-290.
  • Won KB, Heo R, Park HB, et al. Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors. Atherosclerosis. 2021;324:46-51.
  • Mao Q, Zhou D, Li Y, Wang Y, Xu SC, Zhao XH. The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-ST-segment elevation acute coronary syndrome. Dis Markers. 2019;2019:6891537.
  • Nam JS, Kim MK, Nam JY, et al. Association between the atherogenic index of plasma and coronary artery calcification progression in Korean adults. Lipids Health Dis. 2020;19(1):1-7.
  • Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 20017;17(11):1410-1422.
  • Cheng JM, Suoniemi M, Kardys I, et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015;243(2):560-566.
  • Yan PF, Liu L, Yuan J, Xu CX, Song D, Yan H. The racial differences in the clinical outcomes of intravascular ultrasound-guided percutaneous coronary intervention: a systematic review and meta-analysis. Am J Cardiol. 2023;203:193-202.
  • 15. Saito Y, Kobayashi Y, Fujii K, et al. CVIT 2023 clinical expert consensus document on intravascular ultrasound. Cardiovasc Inter Ther. 2023;39(1):1-14.
  • Räber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018;39(35):3281-3300.
  • Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51(6):1908-1919.
  • Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-1252.
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
  • He Y , Li Z, Yu L, et al. Association between the atherogenic index of plasma and carotid artery plaques in patients with coronary heart disease in different glucose metabolism states: an RCSCD-TCM study in Tianjin, China. Endocrine. 2023;81(2):252-261.
  • Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34(7):583-588.
  • Dobiásová M, Frohlich J, Sedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52:566-571.
  • Shen S, Lu Y, Qi H, et al. Association between ideal cardiovascular health and the atherogenic index of plasma. Medicine. 2016;95(24):e3866.
  • Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran. 2015;29:240.
  • Ono M, Kawashima H, Hara H, et al. Advances in IVUS/OCT and future clinical perspective of a novel hybrid catheter system in coronary imaging. Front Cardiovasc Med. 2020;31:7-119.
Toplam 25 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Kardiyoloji
Bölüm Research Articles [en] Araştırma Makaleleri [tr]
Yazarlar

Aslan Erdoğan 0000-0002-1094-5572

Eyüp Özkan 0000-0003-0792-628X

Yayımlanma Tarihi 29 Şubat 2024
Gönderilme Tarihi 17 Ocak 2024
Kabul Tarihi 5 Şubat 2024
Yayımlandığı Sayı Yıl 2024 Cilt: 5 Sayı: 1

Kaynak Göster

AMA Erdoğan A, Özkan E. Examining the relationship between the atherogenic index of plasma and coronary plaque burden: insights from a retrospective intravascular ultrasound analysis. J Med Palliat Care / JOMPAC / Jompac. Şubat 2024;5(1):23-28. doi:10.47582/jompac.1421199

images?q=tbn:ANd9GcRrI_RWgGRe7JRpz3PAnkt2YEFD2l6WEmgHMzuM2w9b&s

f9ab67f.png     

7yziemq.png




COPE.jpg

icmje_1_orig.png

cc.logo.large.png

ncbi.png

ORCID_logo.png

images?q=tbn:ANd9GcQk2AsOdjP67NBkYAqd8FHwCmh0_3dkMrXh3mFtfPKXwIai7h0lIds8QYM9YjKMhZw8iP0&usqp=CAU

logo_world_of_journals_no_margin.png1280px-WorldCat_logo.svg.png                             images?q=tbn:ANd9GcRrI_RWgGRe7JRpz3PAnkt2YEFD2l6WEmgHMzuM2w9b&s


Dergimiz; TR-Dizin ULAKBİM, ICI World of  Journal's, Index Copernicus, Directory of Research Journals Indexing (DRJI), General Impact Factor, Google Scholar, Researchgate, WorldCat (OCLC), CrossRef (DOI), ROAD, ASOS İndeks, Türk Medline İndeks, Eurasian Scientific Journal Index (ESJI) ve Türkiye Atıf Dizini'nde indekslenmektedir.

EBSCO, DOAJ, OAJI, ProQuest dizinlerine müracaat yapılmış olup, değerlendirme aşamasındadır.

Makaleler "Çift-Kör Hakem Değerlendirmesi”nden geçmektedir.

Üniversitelerarası Kurul (ÜAK) Eşdeğerliği: Ulakbim TR Dizin'de olan dergilerde yayımlanan makale [10 PUAN] ve 1a, b, c hariç uluslararası indekslerde (1d) olan dergilerde yayımlanan makale [5 PUAN].

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser.  About predatory/questionable journals and journal charge policy

Not: Dergimiz WOS indeksli değildir ve bu nedenle Q  sınıflamasına dahil değildir.
Yağmacı/şüpheli dergilerle ilgili Yüksek Öğretim Kurumu (YÖK) kararları ve yazar açıklama metni ile dergi ücret politikası: Yağmacı/Şaibeli Dergiler ve Dergi Ücret Politikası